Nutritional Advice El MondoObjectives:
Do COVID-19 patients benefit from the use of remdesivir?
Study design:
This review article included a total of 4 RCTs with 7,334 patients with COVID-19.
Results and conclusions:
The investigators found at a follow-up of 28-29 days from randomization, very low certainty evidence showed that use of remdesivir compared with control group (placebo and/or standard of care) was not associated with a significant decrease in time to clinical improvement [SMD = -0.80 day, 95% CI = -2.12 to 0.53].
The investigators found, however, moderate certainty of evidence showed that remdesivir was associated with higher rates of recovered patients [risk difference = 0.07, 95% CI = 0.05 to 0.08] and discharged patients [risk difference = 0.07, 95% CI = 0.03 to 0.11] and lower rates of developing serious adverse events [risk difference = -0.05, 95% CI = -0.10 to -0.01] compared with control.
The investigators found moderate and very low certainty of evidence showed there was no significant difference in deaths at 28-29 days follow-up [risk difference = -0.01, 95% CI = -0.03 to 0.01] and developing any adverse events [risk difference = 0.01, 95% CI = -0.17 to 0.19] between both groups, respectively.
The investigators concluded COVID-19 patients given remdesivir are more likely to demonstrate recovery and are associated with higher rates of hospital discharge, but not with significant reduction in mean time to clinical improvement or mortality.
Original title:
Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials by Al-Abdouh A, Bizanti A, […], Michos ED.
Link:
https://pubmed.ncbi.nlm.nih.gov/33422642/
Additional information of El Mondo:
Find more information/studies on coronavirus right here.